Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Maria Antista"'
Autor:
Giovanni Fucà, Margherita Ambrosini, Rossana Intini, Maria Antista, Matteo Fassan, Giuseppe Curigliano, Alessandra Anna Prete, Marta Brambilla, Andrea Spallanzani, Federica Morano, Massimiliano Salati, Carmen Belli, Filippo Pietrantonio, Elisabetta Fenocchio, Beatrice Borelli, Sara Lonardi, Vittorina Zagonel, Francesca Corti, Filippo de Braud, Virginia Quarà
Publikováno v:
European Journal of Cancer. 150:155-167
Immune checkpoint inhibitors (ICIs) yielded unprecedented efficacy in patients with microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC). Since the Pan-Immune-Inflammation Value (PIV) is a blood-based biomarker with prognostic us
Autor:
Lorenza Rimassa, Sara Lonardi, Filippo Pagani, Federica Morano, Filippo de Braud, Giovanni Randon, Gianluca Tomasello, Giuseppina Calareso, Francesca Bergamo, Alberto Zaniboni, Michele Prisciandaro, Marta Vaiani, Salvatore Corallo, Maria Di Bartolomeo, Paolo Manca, Carlotta Antoniotti, Valeria Smiroldo, Maria Antista, Chiara Cremolini, Marco Tampellini, Matteo Clavarezza, Francesca Greco, Filippo Pietrantonio, Federica Palermo, Roberto Murialdo, Alessandra Raimondi, Patrizia Racca
Publikováno v:
European Journal of Cancer. 144:31-40
In patients with metastatic colorectal cancer (mCRC) receiving highly active first-line combination treatments, early tumor shrinkage (ETS) and depth of response (DoR) are associated with survival, but their influence on outcomes during maintenance t
Autor:
Melissa Anna Teresa Monica, Sara Pusceddu, Sara Manglaviti, Federico Nichetti, Filippo de Braud, Vincenzo Mazzaferro, Natalie Prinzi, Maria Di Bartolomeo, Marta Brambilla, Martina Torchio, Monica Niger, Jorgelina Coppa, Maria Antista, Laura Cattaneo, Francesca Corti, Michele Prisciandaro
Publikováno v:
World Journal of Gastrointestinal Oncology
Exocrine pancreatic neoplasms represent up to 95% of pancreatic cancers (PCs) and are widely recognized among the most lethal solid cancers, with a very poor 5-year survival rate of 5%-10%. The remaining < 5% of PCs are neuroendocrine tumors that are
Autor:
Filippo Pagani, Monica Niger, Alessio Amatu, Monica Giordano, Marco Tampellini, Salvatore Corallo, Patrizia Racca, Giovanni Randon, Giuseppe Toscano, Saverio Cinieri, Lorenza Rimassa, Alessandra Raimondi, Maria Di Bartolomeo, Matteo Clavarezza, Carlotta Antoniotti, Lorenzo Antonuzzo, Gianluca Tomasello, Maria Antista, Filippo Pietrantonio, Michele Prisciandaro, Filippo de Braud, Fausto Petrelli, Margherita Ambrosini, Sara Lonardi, Raffaella Longarini, Roberto Murialdo, Alberto Zaniboni, Federica Morano
The combination of anti-EGFRs and doublet chemotherapy is considered the optimal upfront option for patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC). The prophylactic or reactive treatment with tetracyclines for EGFR in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45ae4c14feb0bd3845d079f92ac94286
http://hdl.handle.net/11568/1072416
http://hdl.handle.net/11568/1072416
Autor:
Francesca Corti, Luca Giacomelli, Natalie Prinzi, Filppo de Braud, Jorgelina Coppa, Michele Prisciandaro, Martina Torchio, Massimo Milione, Michela Monteleone, Sara Pusceddu, Claudio Vernieri, Maria Di Bartolomeo, Monica Niger, Maria Antista, Elena Colombo
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 13 (2020)
Therapeutic Advances in Gastroenterology
Therapeutic Advances in Gastroenterology
The incidence of pancreatic neuroendocrine tumors (panNETs) has increased worldwide in the last two decades. Given the indolent nature of these tumors, several patients are diagnosed with metastatic disease, which partially impairs the long-term effi
Autor:
Alessandra Raimondi, Filippo de Braud, Salvatore Corallo, Laura Cattaneo, Giovanni Fucà, Massimiliano Salati, Massimo Milione, Maria Di Bartolomeo, Riccardo Lobefaro, Vincenzo Guarini, Maria Antista, Vincenzo Mazzaferro, Michele Prisciandaro, Carlo Sposito, Andrea Spallanzani, Federica Morano, Filippo Pietrantonio, Desirè Viola Trupia, Chiara C. Volpi, Annunziata Gloghini
Publikováno v:
Oncologist
Background Epstein-Barr virus (EBV)-positive gastric cancers (GCs) have been recently identified as a molecular subgroup showing excellent outcomes after surgery for early-stage disease and responsiveness to immune checkpoint inhibitors (ICIs) for me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a53e5b85a47a41a9f977d3118f99a3b8
https://europepmc.org/articles/PMC7485344/
https://europepmc.org/articles/PMC7485344/
Autor:
Alessandra Raimondi, Lorenza Rimassa, Francesca Bergamo, Carlotta Antoniotti, Matteo Clavarezza, Monica Niger, Vincenzo Adamo, Roberto Murialdo, Filippo Pietrantonio, Massimo Di Maio, Andrea Sartore-Bianchi, Giorgia Peverelli, Maria Antista, Saverio Cinieri, Monica Giordano, Fausto Petrelli, Marco Tampellini, Salvatore Corallo, Maria Di Bartolomeo, Sara Lonardi, Lorenzo Antonuzzo, Gianluca Tomasello, Filippo de Braud, Raffaella Longarini, Giuliana Ritorto, Federica Morano, Alberto Zaniboni
Background Quality of life (QoL) patient-reported outcomes (PROs) data from pivotal first-line trials in metastatic colorectal cancer (mCRC) are poor. The Valentino study showed that de-escalation to single-agent panitumumab after 4-month induction w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cece534f8a34f890c25303db0d3ec650
http://hdl.handle.net/2318/1770066
http://hdl.handle.net/2318/1770066
Autor:
Stefania Mosconi, Marco Macagno, Gabriella Farina, Stefania Gori, Vincenzo Guarini, Ludovic Barault, Sabina Murgioni, Federica Palermo, Andrea Sartore-Bianchi, Filippo Pietrantonio, Federica Perrone, Massimo Di Maio, Giovanni Fucà, Sara Lonardi, Federica Morano, Giovanni Randon, Riccardo Lobefaro, Fausto Petrelli, Salvatore Corallo, Maria Di Bartolomeo, Filippo de Braud, Gianluca Tomasello, Federica Di Nicolantonio, Massimo Milione, Filippo Pagani, Raffaella Longarini, Lorenza Rimassa, Maria Antista, Antonia Martinetti, Elena Tamborini, Alessandra Raimondi
Purpose: To determine whether second-line therapy with capecitabine and temozolomide was superior to irinotecan, leucovorin, and fluorouracil (FOLFIRI) in patients with RAS-mutated, methyl-guanine methyltransferase (MGMT)-methylated metastatic colore
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bb27299cdd68061f7604a5a53623d3d
http://hdl.handle.net/2318/1729965
http://hdl.handle.net/2318/1729965
Autor:
Maria Antista, E. Campi, Francesca Corti, Daniele Rossini, Beatrice Borelli, Veronica Conca, Gianluca Masi, Alessandra Boccaccino, Marco Maria Germani, Alfredo Falcone, Mirella Giordano, Carlotta Antoniotti, Elisa Sottotetti, C. Cremolini, A. Martinetti, Nadia Zaffaroni, Gemma Zucchelli, Federica Marmorino, Filippo Pietrantonio, Roberto Moretto
Publikováno v:
Annals of Oncology. 32:S211
Autor:
Daniele Rossini, Mirella Giordano, Carlotta Antoniotti, Nadia Zaffaroni, Chiara Cremolini, Beatrice Borelli, Alessandra Boccaccino, Alfredo Falcone, Marco Maria Germani, Elisa Sottotetti, Veronica Conca, Antonia Martinetti, Roberto Moretto, Gianluca Masi, Maria Antista, Francesca Corti, Gemma Zucchelli, Filippo Pietrantonio, Federica Marmorino, Elisa Campi
Publikováno v:
Journal of Clinical Oncology. 39:e15566-e15566
e15566 Background: Regorafenib is a treatment option for refractory mCRC patients with no validated predictors of benefit. We previously showed that, among several circulating angiogenic factors, low baseline Ang-2 and Tie-2 plasma levels were associ